Abstract
Objective Fontan surgical planning involves designing grafts to perform optimized hemodynamic performance for the patient’s long-term health benefit. The uncertainty of post-operative boundary conditions (BC) and graft anastomisis displacements may significantly affect the optimized graft designs and lead to undesired outcomes, especially for hepatic flow distribution (HFD). We aim to develop a computation framework to automatically optimize patient-specific Fontan grafts with the maximized possibility of keeping the post-operative results within clinical acceptable thresholds.
Methods The uncertainties of BC and anastomosis displacements were modeled by using Gaussian distributions according to prior research studies. By parameterizing the Fontan grafts, we built surrogate models of hemodynamic parameters by taking the design parameters and BC as inputs. A two-phased reliability-based robust optimization (RBRO) strategy was developed by combining deterministic optimization (DO) and optimization under uncertainty (OUU) to reduce the computation cost.
Results We evaluated the performance of the RBRO framework by comparing it with the DO method on four Fontan patient cases. The results showed that the surgical plans computed from the proposed method yield up to 79.2% improvement on the reliability of HFD than those from the DO method (p < 0.0001). The mean values of iPL and %WSS satisfied the clinically acceptable thresholds.
Conclusion This study demonstrated the effectiveness of our RBRO framework to address uncertainties of BC and anastomosis displacements for Fontan surgical planning.
Significance The technique developed in this paper demonstrates a significant improvement in the reliability of predicted post-operative outcomes for Fontan surgical planning. This planning technique is immediately applicable as a building block to enable technology for optimal long-term outcomes for pediatric Fontan patients and can also be used to other pediatric and adult cardiac surgeries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Maryland Innovation Initiative Award 1120-04, NIH NHLBI-R01HL143468, R21/R33HD090671
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(e-mail: xiaolong{at}jhu.edu)
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos